Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CEO Sells 12,385 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) CEO Laura Francis sold 12,385 shares of the business’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $19.67, for a total transaction of $243,612.95. Following the completion of the transaction, the chief executive officer now owns 495,170 shares in the company, valued at approximately $9,739,993.90. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Laura Francis also recently made the following trade(s):

• On Monday, May 19th, Laura Francis sold 5,412 shares of SI-BONE stock. The stock was sold at an average price of $19.49, for a total value of $105,479.88.
• On Wednesday, May 7th, Laura Francis sold 38,504 shares of SI-BONE stock. The shares were sold at an average price of $17.18, for a total value of $661,498.72.

SI-BONE Stock Performance

Shares of SI-BONE stock opened at $19.71 on Wednesday. The firm has a fifty day moving average of $15.02 and a two-hundred day moving average of $15.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a market capitalization of $839.94 million, a price-to-earnings ratio of -21.42 and a beta of 0.82. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $20.05.

SI-BONE (NASDAQ:SIBN) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. As a group, equities research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

SIBN has been the topic of a number of recent analyst reports. Truist Financial boosted their price objective on SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th.

Institutional Trading of SI-BONE

A number of hedge funds have recently modified their holdings of SIBN. Nuveen LLC bought a new stake in SI-BONE in the first quarter valued at approximately $18,605,000. First Light Asset Management LLC grew its holdings in shares of SI-BONE by 41.8% in the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company’s stock valued at $22,622,000 after buying an additional 475,426 shares during the period. Silvercrest Asset Management Group LLC increased its position in shares of SI-BONE by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock valued at $27,392,000 after buying an additional 350,970 shares in the last quarter. American Century Companies Inc. increased its position in shares of SI-BONE by 11.1% in the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company’s stock valued at $37,072,000 after buying an additional 264,254 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in SI-BONE by 55.0% during the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock worth $8,861,000 after buying an additional 224,190 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.